Artiva Biotherapeutics, Inc. (ARTV) Stock Price & Analysis
Artiva Biotherapeutics, Inc. (ARTV) rose 0.58% to USD 11.19 as of September 8, 2026 at 05:44 UTC, according to Nexqual real-time market data.
ARTV last closed at USD 11.13; the session ranged USD 10.94–11.34 on volume of 168,592 shares. Market capitalization is $547.08M, with a 52-week range of USD 2.22–14.53 (NGM). Source: Nexqual, September 8, 2026 at 05:44 UTC.
Key Statistics (as of September 8, 2026 at 05:44 UTC)
| Price | USD 11.19 |
|---|---|
| Change | ▲ 0.58% (up) |
| Previous Close | USD 11.13 |
| Open | USD 11.02 |
| Day Range | USD 10.94 – 11.34 |
| 52-Week Range | USD 2.22 – 14.53 |
| Volume | 168,592 shares |
| Market Cap | $547.08M |
| Exchange | NGM |
Technical Analysis (ARTV)
Nexqual's technical model rates ARTV "NEUTRAL" based on 3 bullish and 2 bearish signals across 128 daily candles, as of September 8, 2026 at 05:44 UTC.
| Overall Signal | NEUTRAL |
|---|---|
| RSI (14) | 51.75 (neutral) |
| vs SMA50 | Above (USD 10.57) |
| MACD | 0.18 (positive) |
Analyst Ratings (ARTV)
Wall Street analysts rate ARTV "None" based on 5 analysts, with a mean price target of USD 35.8 (range USD 23–41), per Nexqual as of September 8, 2026 at 05:44 UTC.
| Consensus Rating | None |
|---|---|
| Analyst Count | 5 |
| Mean Target | USD 35.8 |
| High Target | USD 41 |
| Low Target | USD 23 |
| Buy / Hold / Sell | 6 / 0 / 0 |
Earnings (ARTV)
| EPS Estimate | USD -0.53 |
|---|---|
| Revenue Estimate | $0 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD -0.63 vs est -0.64 ▲ beat |
| 2026-03-31 | USD -0.95 vs est -0.84 ▼ miss |
| 2025-12-31 | USD -0.84 vs est -0.8 ▼ miss |
| 2025-09-30 | USD -0.88 vs est -0.8 ▼ miss |
Source: Nexqual, September 8, 2026 at 05:44 UTC.
Financials & Fundamentals (ARTV)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -36.58% |
| Debt / Equity | 2.83 |
| Current Ratio | 24.16 |
| Total Cash | $349.39M |
| Total Debt | $9.85M |
| Free Cash Flow | $-44.43M |
Source: Nexqual, September 8, 2026 at 05:44 UTC.
Financial Health Score (ARTV)
Nexqual rates Artiva Biotherapeutics, Inc.'s overall financial health "Weak" across five dimensions, as of September 8, 2026 at 05:44 UTC.
| Growth | Critical — Revenue -100% YoY (annual), sharp decline |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Strong — $349M cash vs $10M debt, net cash position |
| Cash Flow | Weak — Operating cash flow -$75M |
| Efficiency | Critical — ROE -37%, ROA -22.3% |
Ownership (ARTV)
| Insider Ownership | +14.88% |
|---|---|
| Institutional Ownership | +84.17% |
| Shares Outstanding | 48.89M |
| Float | 19.63M |
| Short % of Float | +6.11% |
Source: Nexqual, September 8, 2026 at 05:44 UTC.
Leadership (ARTV)
Artiva Biotherapeutics, Inc. is led by Fred Aslan (age 50), CEO, Principal Financial & Accounting Officer and Director, per Nexqual as of September 8, 2026 at 05:44 UTC.
| CEO, Principal Financial & Accounting Officer and Director | Fred Aslan (age 50) |
|---|---|
| President and Head of Research & Development | Gines Diego Miralles (age 62) |
| Chief Operating Officer | Jennifer Kinsbruner Bush Esq. (age 50) |
| Vice President of Corporate Development | Nicholas Veomett |
| Senior Vice President of Research & Early Development | Heather Raymon (age 60) |
Major Backers & Investors (ARTV)
Notable institutional backers of Artiva Biotherapeutics, Inc. include RA Capital Management, L.P., Viking Global, Blackstone Inc, according to Nexqual as of September 8, 2026 at 05:44 UTC.
Active Investors
| Investor | Stake |
|---|---|
| RA Capital Management, L.P. | 36.73% |
| Viking Global | 5.33% |
| Blackstone Inc | 4.92% |
| 5AM Venture Management, LLC | 4.81% |
| Venrock Adviser, LLC | 4.18% |
| Franklin Resources, Inc. | 4.09% |
| Caligan Partners, LP | 3.55% |
| Samsara BioCapital, LLC | 1.95% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 3.99% |
Source: Nexqual, September 8, 2026 at 05:44 UTC.
From Artiva Biotherapeutics, Inc.'s Latest SEC 10-K Filing (filed 2026-03-10)
Key Strengths & Strategy (as disclosed to the SEC)
- Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers.
- Its lead product candidate includes AlloNK, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as rheumatoid arthritis, systemic lupus erythematosus, lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody -associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, and B-cell-non-Hodgkin lymphoma.
- The company also develops AB-201, an allogeneic anti- human epidermal growth factor receptor 2 targeting chimeric antigen receptor (CAR)-NK cell product candidate for the treatment of various solid tumors, such as breast, gastric and esophageal, and bladder cancers; and AB-205, an allogeneic anti-CD5 CAR-NK cell product candidate for the treatment of hematological malignancies.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| ALMS | Alumis Inc. | USD 11.1 | ▲ 7.25% |
| KYTX | Kyverna Therapeutics, Inc. | USD 8.25 | ▼ 4.24% |
| ANRO | Alto Neuroscience, Inc. | USD 35.55 | ▼ 2.97% |
| QTTB | Q32 Bio Inc. | USD 11.99 | ▼ 11.77% |
| MBX | MBX Biosciences, Inc. | USD 61.72 | ▲ 1.36% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 8, 2026 at 05:44 UTC. This page is informational and not investment advice.